On November 20, 2019 Oncoceutics, Inc. reported that new data will be presented on the efficacy and mechanism of action of imipridones ONC201 and ONC206 at the 24nd Annual Scientific Meeting of the Society of Neuro-Oncology, to be held November 20th-24th in Phoenix, Arizona (Press release, Oncoceutics, NOV 20, 2019, View Source [SID1234558320]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
These data will highlight exciting findings that have emerged over the past year, including:
Updated clinical results for ONC201 in pediatric and adult H3 K27M-mutant gliomas
Extension of ONC201 activity to other brain tumors
Synergy antitumor activity of ONC201 in combination with other treatments
Activity of ONC206 in medulloblastoma
IND-enabling studies with ONC206
Distinctions in the activity of ONC201 and ONC206
Inhibition of mitochondrial function by ONC201
The capability of the imipridone family to bind to distinct molecular targets
Oncoceutics and academic investigators will present a range of results with imipridones that will include mechanistic and efficacy findings from preclinical models that detail their unique therapeutic potential in neuro-oncology. In addition, updated safety, pharmacokinetic, pharmacodynamic, and efficacy results from clinical trials with ONC201 in high-grade glioma patients will be reported. These results are largely derived from the ongoing clinical program that is dedicated to exploring ONC201 a molecularly-defined patient population (H3 K27M-mutant glioma). The rationale for the upcoming first-in-human clinical trial of ONC206 in adult recurrent CNS tumors will also be highlighted.
Summaries and presentation information are provided below:
Date/Time Location Abstract Title Presenter
Wednesday 11/20
9:40 – 9:50 PM JW Marriott Selective targeting of dopamine receptor dysregulation in high grade gliomas with ONC201 Varun Prabhu, PhD, Oncoceutics
Thursday 11/21
5:00 – 7:00 PM Investigator Meeting
Friday 11/22
7:30 – 9:30 PM Ballroom Lawn Imipridone Structure Activity Relationship Uncovers ONC206 as the Next Bitopic DRD2 Antagonist for Oncology with Differentiated Receptor Pharmacology Varun Prabhu, PhD, Oncoceutics
7:30 – 9:30 PM Ballroom Lawn Single agent ONC201 in previously treated, progressive adult H3 K27M-mutant glioma Isabel Arrillaga-Romany, MD, PhD, MGH
7:30 – 9:30 PM Ballroom Lawn Role of ONC206 in regulating medulloblastoma tumor progression Anshu Malhotra, PhD, Emory University
7:38 – 7:42 PM Wildflower B Receptor pharmacology of ONC201: The first bitopic DRD2 antagonist for clinical neuro-oncology Josh Allen, PhD, Oncoceutics
Saturday 11/23
7:15 – 8:30 AM Grand Canyon 8-13 H3K27M glioma and ONC201 (SNO-EANO Joint session) Isabel Arrillaga-Romany, MD, PhD, MGH
3:45 – 3:55 PM Grand Canyon 1-6 Clinical efficacy of ONC201 in thalamic H3 K27M-mutant glioma Carl Koschmann, MD, Michigan Medicine
4:40 – 4:45 PM Grand Canyon 1-6 Phase I clinical trial of ONC201 in pediatric H3 K27M-mutant glioma or newly diagnosed DIPG Sharon Gardner, MD, NYU Langone Health
5:00 – 7:00 PM Ballroom Lawn Preclinical combination of ONC201 with radiotherapy or Temozolomide in GBM, DIPG and ATRT cell lines results in dopamine receptor antagonism, ATF4 induction and cell death Lanlan Zhou, MD, PhD, Brown University
5:00 – 7:00 PM Ballroom Lawn Metabolic rewiring by ONC201/TIC10 and 2-Deoxyglucose has synergistic anti-glioblastoma activity Josh Allen, PhD, Oncoceutics
5:00 – 7:00 PM Ballroom Lawn PDTM-25 Study of ONC201 in pre-clinical models of DIPG Wafik Zaky, MD, MD Anderson
5:00 – 7:00 PM Ballroom Lawn IND-enabling Characterization of ONC206 as the Next Bitopic DRD2 antagonist for Neuro-oncology Varun Prabhu, PhD, Oncoceutics